Ascletis Believes that the Complaints Made by Viking Therapeutics Have No Merit and will Vigorously Defend Against such Complaints
HANGZHOU and SHAOXING, China, Jan. 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") was recently informed that on December 29, 2022, Viking Therapeutics, Inc. ("Viking"), a pharmaceutical company in the United States, filed certain complaints against Ascletis, its founder Dr. Jinzi Jason WU and certain subsidiaries of Ascletis in connection with the drug candidates ASC41 and ASC43F....
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
GAITHERSBURG, Md., Dec. 31, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of a Phase 2 trial for its COVID-19-Influenza Combination (CIC) and influenza stand-alone vaccine candidates. The dose-confirming trial will evaluate the safety and effectiveness...
Mentice AB (publ) receives an order of USD 540,000 for simulation solutions from Corewell Health, Grand Rapids, Michigan, USA
GOTHENBURG, Sweden, Dec. 30, 2022 /PRNewswire/ -- Mentice AB (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that Corewell Health, Grand Rapids, Michigan USA, has signed an agreement to acquire Mentice VIST® simulation solutions for an order of USD 540,000. For more information, please contact: Göran Malmberg, CEO, MenticeE-post: goran.malmberg@mentice.com US Mobile. +1 (312) 860...
Grand Pharma Announces Successful Clinical Progress of its Oral 3CL Protease Inhibitor GS221 Against COVID-19
GS221 has conducted 3 clinical trials. Current results of clinical trials show favorable safety and tolerance in the subjects. After administration, the patients showed trends of improvement of clinical symptoms, shortening time for negative nucleic acid test, and rapid decline of viral load; After GS221 being successfully approved for commercialization, it is expected to become a broad-spectrum oral...
Everest Medicines to Hold New Corporate Strategy Online Conference Calls
SHANGHAI, Dec. 30, 2022 /PRNewswire/ -- Everest Medicines (HKEX: 1952), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced that the Company's management will host conference calls to introduce its new corporate strategy. Mr. Rogers Luo, Chief Executive Officer of Everest Medicines and Mr. Ian Woo, President and Chief Financial Officer, will provide...
Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy
--Further regulatory support for accelerated approval of Nefecon following NMPA's NDA acceptance with Breakthrough Therapy Designation— SHANGHAI, Dec. 30, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines in Greater China and other parts of Asia, announced today that the Center for Drug Evaluation (CDE) of the China National...
Complete Genomics to Present its Multiple, Innovative Sequencing Platforms at BIOTECH SHOWCASE™ 2023
Enhanced sequencing capabilities offer opportunity to accelerate breakthroughs in life science research SAN JOSE, Calif., Dec. 30, 2022 /PRNewswire/ -- Complete Genomics Inc（https://completegenomics.mgiamericas.com/）, a subsidiary of MGI Tech Co., Ltd., today announced that it is presenting at Biotech Showcase™ 2023, taking place in San Francisco at the same time as the JP Morgan healthcare conference. Registered attendees can view...
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office
- Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkinson's and Alzheimer's - MELBOURNE, Australia and SAN FRANCISCO, Dec. 29, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that a new...
China enters new stage in COVID-19 response
BEIJING, Dec. 29, 2022 /PRNewswire/ -- A news report by China.org.cn on China's COVID-19 response:   Changes are taking place to China's COVID-19 response. Now, efforts are being accelerated across the country to fully reopen the economy, and people are generally no longer required to present their nucleic acid test results when entering workplaces and public spaces or...
WeTrade Group Pushes Further into the New Energy Cooperated with Super Solar Energy
BEIJING, Dec. 29, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), a global diversified "software as a service" ("SaaS") technology service provider committed to providing technical support and digital transformation tools for enterprises across different industries, today announced that the Company has entered into strategic cooperation with Fujian Super Solar Energy Technology Co., Ltd ("Fujian...
